Source: https://www.malignanttumors.org/jour/article/view/167
Timestamp: 2019-04-21 01:09:54+00:00

Document:
1. Сотников В. М. Лучевая терапия в современных программах лечения неходжкинских лимфом: автореф. дисс. … докт. мед. Наук 14.00.19. М., 1996. – 36 с.
2. Трофимова О. П., Ткачев С. И., Юрьева Т. В. Прошлое и настоящее лучевой терапии в онкологии. Клиническая онкогематология. – 2013.– Т. 6, № 4.– С. 355–364.
3. Horning S. et al. Chemotherapy with or without radiotherapy in limited stage diffuse aggressive non-Hodgkin’s lymphoma: ECOG 1484. J. Clin. Oncol. – 2004.– V. 22.– P. 3032–3038.
4. Miller T. P. Chemotherapy alone vs chemotherapy plus radiotherapy for localized intermediate – and high grade nonHodgkin’s lymphoma. N. Engl. J. Med. – 1998.– V. 339.– P. 21–26.
5. Phan J. et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J. Clin. Oncol. – 2010.– V. 28 (27).– P. 4170–4176.
6. Aviles A. et al. Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int. J. Radiat. Oncol. Biol. Phys. – 1994.– V. 30.– P. 799–803.
7. Aviles A. et al. Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma. – 2004. – № 45.– P. 1385–1389.
8. Held G. et al. The impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. Hematological oncology. – 2013.– V. 31 (Suppl. 1).– p. 129. (abst. 098).
9. Виноградова Ю. Н., Ильин Н. В. Значение лучевой терапии в химиолучевом лечении нодальных диффузных крупноклеточных В-клеточных неходжкинских лимфом. Вопросы онкологии. – 2015.– Т. 61, № 1.– с. 96–101.
10. Yahalom J. Principles, Indications, and Techniques of Radiation therapy of Lymphomas. The Lymphomas (Second Edition) / Ed. G. Canellos T. A., Lister B. Young – 2006.– P. 203–224.
11. Todeschini G. et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br. J. Cancer. – 2004.– V. 90, № 2.– P. 372–376.
12. Dunleavy K. et al.The addition of rituximab to dose-adjusted (DA)– epoch obviates the need for radiation in the treatment of primary mediastinal large B-cell lymphoma (PMBL): of prospective study of 58 patients. Ibid. – 2008.– V. 19 (Suppl. 4).– p. 96.
13. Dunleavy K. et al. Dose adjusted EPOCH-R-Rituximab therapy in Primary Mediastinal B-Cell Lymphoma. N. Engl. J. Med. – 2013. – 368 (15).– P. 1408–1416.
14. Martelli M. et al. МАСОР-В ± /-RITUXIMAB followed by involved mediastinal radiotherapy is a safe and high effective therapy for primary mediastinal large В-cell lymphoma (PMBL) long term results and late toxicity from EPOCH-R without radiation single Italian center. Ibid. – 2011.– V. 22. (Suppl. 4).– p. 134.
15. Dabrowska-Iwanica A. et al. Treatment of primary mediastinal B-cell lymphoma – a multicenter retrospective analysis on behalf of the Polish Lymphoma Research Group. Ann. Oncol. – 2011.– V. 9 (Suppl. 4).– P. 1165–11196.
16. Martelli M. et al. A randomized multicenter, two arm phase III comparative study assessing the role of mediastinal radiotherapy after rituximab-containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMBCL): The IELSG 37 study. Hematol. Oncol. – 2013.– p. 140 (abst. 133).
17. Виноградова Ю. Н. Значение лучевой терапии при химиолучевом лечении больных неходжкинскими лимфомами. Автореф. дисс. … д-ра мед. наук 14.00.13. СПб, 2015. – 43 с.
18. Поддубная И. В. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний / под рук. проф. И. В. Поддубной и В. Г. Савченко. Современная онкология. Экстра выпуск, 2013. – 102 с.
19. Ferreri A. J., Radford J., Doglioni C., Ponzoni M. MALT-type lymphoma of the orbit and ocular adnexae. In: Extranodal Lymphomas (Pathology and Management) / Ed. F. Cavalli, H. Stein, E. Zucca – 2008.– P. 244–264.
20. Ohga S. et al. Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma. Anticancer Res. – 2013. – 33 (12). – P. 5575–5578.
21. Harada K. et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a longterm outcome in 86 patients with 104 treated eyes. Int. J. Radiat. Oncol. Biol. Phys. – 2014.– V. 88, № 3.– P. 650–654.
22. Cho W. K. et al. Risk potentiality of frontline radiotherapy associated cataract in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma. Korean. J. Ophthalmol. – 2013. – 27 (4). – P. 243–248.
23. Вернюк М. А. и др. Первичные неходжкинские лимфомы желудочно-кишечного тракта. Вопросы онкологии. – 2013.– Т. 59, № 3 (приложение) – с. 1135.
24. Neubauer A., Zucca E. Gastrointestinal tract lymphomas. Int.: Extranodal lymphomas / Ed. F. Cavalli, H. Stein, E. Zucca – 2008.– P. 233–243.
25. Haim N. et al. Intermediate and high-grade gastric non-Hodgkin’s lymphoma a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy. Leuk Lymphoma. – 1995. – 17.– P. 321–326.
26. Thiede С. et al. Persistence of monoclonal В cells after cure of Hehcobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J. Clin. Oncol. – 2001.– Vol. 19.– P. 1600–1609.
27. Wundisch T. et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J. Clin. Oncol. – 2005.– V. 23.– P. 8018–8024.
28. Morgner A. et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Hehcobacter pylori infection. J. Clin. Oncol. – 2001.– V. 19.– P. 2041–2048.
29. Taа1 B.G. et al. The clinical spectrum and treatment of primary non-Hodgkin’s ymphoma of the stomach [see comments]. Ann. Oncol. – 1993.– V. 4.– P. 839–846.
30. Koch P. et al. Treatment results in localized primarу gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J. Clin. Oncol. – 2005.– V. 23.– P. 7050–7059.
31. Schmidt W. P., Schmitz N., Sonnen R. Conservative management of gastric lymphoma: the treatment option of choice. Leuk Lymphoma. – 2004.– V. 45.– P. 1847–1852.
32. Conconi A. et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. – 2003.– V. 102.– P. 2741–2745.
33. Вотякова О. М. Множественная миелома. В кн.: Руководство по химиотерапии опухолевых заболеваний. // Под ред. Н. И. Переводчиковой.– М, 2011.– С. 362–372.
34. Бессмельцев С. С. Множественная миелома (лечение первичных больных): обзор литературы и собственные данные. Часть II. Клиническая онкогематология. – 2013.– Т. 6, № 4.– С. 379–414.
35. Каприн А. Д., Старинский В. В., Петрова Г. Р. Состояние онкологической помощи населению России в 2012 году. М., 2013. – 232 с.
36. Мерабишвили В. М. Онкологическая служба Санкт-Петербурга. Популяционный раковый регистр (IACR № 221). СПб, 2013.– Т. 18. – 362с.
37. Виноградов В. М. Состояние радиотерапевтической помощи онкологическим больным в Санкт-Петербурге. Лучевая диагностика и терапия. 2014. – № 3 (5).– С. 5–11.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.